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The synthesis of the diamine putrescine, and the polyamines sper-
midine and spermine, is of vital importance for cell proliferation.
Due to their polycationic nature, polyamines interact with various
macromolecules and influence multiple cellular functions. Growth
stimuli strongly induce polyamine biosynthesis, which appears to
be a prerequisite for cell proliferation. Tumour cells appear to have
an altered polyamine homeostasis reflected by increased activity
of biosynthetic enzymes and elevated polyamine pools (Porter et
al, 1992). Hence, the two rate-limiting enzymes of polyamine
biosynthesis, ornithine decarboxylase (ODC) (McCann and Pegg,
1992) and S-adenosylmethionine decarboxylase (SAMDC) (Pegg
and McCann, 1992) have been selected as potential therapeutic
targets for cancer chemotherapy. The polyamine biosynthesis
pathway is depicted in Figure 1. Since the early 1960s, preclinical
and clinical trials have been undertaken with the SAMDC
inhibitor, methylglyoxal bis(guanylhydrazone) (MGBG) in cancer
indications. Responses were noted in a broad spectrum of malig-
nant diseases, including acute leukaemia, chronic myelogenous
leukaemia, lymphoma, multiple myeloma, head and neck cancer,
and oesophageal cancer. However, toxicity was marked and
consisted of myelosuppression and mucositis, as well as mito-
chondrial toxicity (Warrell and Burchenal, 1983). Because of
MGBG’s unfavourable safety profile, new SAMDC inhibitors
were sought with improved potency and specificity.
SAM486A (CGP 48664) is the free base of 4-(aminoimino-
methyl)-2,3-dihydro-1H-inden-1-one-diaminomethylenehydra-
zone whose salt with D,L-lactic acid was the formulation used for
intravenous administration in this study. In vitro, this compound is
a potent, selective inhibitor of SAMDC, with an IC50 of 4.7 nM,
being approximately 200-fold more active than MGBG (Regenass
et al, 1994). It showed growth inhibitory activity against a variety
of different tumour cell lines (IC50 in the micromolar range),
including multi-drug-resistant and highly metastatic variants (H
Mett, unpublished data). In in vivo mice xenograft or orthotopic
tumour experiments, doses of SAM486 ranging from 5–
25 mg kg–1 day–1 given intraperitoneally inhibited tumour growth
(Regenass et al, 1994; Dorhout et al, 1995; Gutman et al, 1995;
Manni et al, 1995; Delworth et al, 1997; Svensson et al, 1997; Mi
et al, 1998). Further xenograft experiments suggested that a daily
schedule was associated with a better tumour growth control as
compared to an intermittent schedule (data on file). Additive to
synergistic effects both in vitro and in vivo were observed when
SAM486A was combined with 5-fluorouracil (5FU) and with
cisplatin (Gschaidmeier et al, 1999, O’Reilly et al, 2000). Tumours
of treated L-1210 leukaemia-bearing animals showed decreased
SAMDC activity and elevated putrescine pools (Dorhout et al,
1995). In toxicology studies, short-term single or repeat dose treat-
ment of rats and dogs with bolus injections of high doses of
SAM486A induced acute cardiovascular and respiratory symp-
toms, described as hyperaemia, tachycardia, cyanosis, reduced
body temperature, and dyspnoea, gasping, deep respiration,
respectively. After long-term treatment, heterogenous ECG alter-
ations in dogs were observed, together with morphological
changes in liver and heart. Clearance of SAM486A from plasma of
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doi: 10.1054/ bjoc.2000.1305, available online at http://www.idealibrary.com on rats and dogs was multi-exponential with extensive distribution
outside the plasma compartment, and a high uptake into the liver
and salivary glands was seen. SAM 486A was hardly metabolized
and predominantly renally excreted. Furthermore, as compared to
the plasma elimination profile, a marked accumulation of the drug
was seen in tumours of nude mice subcutaneously transplanted
with the human HCT-116 tumour cell line (data on file).
Three clinical phase I trials have been initiated to characterize
the tolerability, safety and maximum tolerated dose of SAM486A
evaluating three different schedules of administration. In addition
to the xenograft data described above, the observation that
SAMDC activity recovered very rapidly after withdrawal of
SAM486A suggests that a continuous exposure of the drug may be
desirable to achieve an optimal control of tumour growth.
Accordingly, two of the trials investigated regimens designed to
achieve continuous drug exposure: a daily infusion over 5 consec-
utive days every 3 weeks (Siu et al, 1998) and a 120 h continuous
intravenous schedule given every 4 weeks as reported in the
present study, of which preliminary results were presented at the
1998 ASCO meeting (Paridaens et al, 1998). Based on the clinical
experience with MGBG where a weekly administration turned out
to be better tolerated (Warrell and Burchenal, 1983), the third study
investigated a weekly administration schedule (Greim et al, 1998).
Results from this study and the two parallel phase I studies will be
used as the basis for dosage and schedule selection and for the
safety evaluation of SAM486A in the future clinical programme.
PATIENTS AND METHODS
Patients
Patients aged 18 or more with any type of histologically confirmed
solid tumour (including lymphoma), which was refractory to
conventional therapy or for which no standard therapy existed,
were eligible. In addition, patients needed to have a WHO
performance status of 0–2, a life expectancy of ≥ 3 months, and
normal hepatic, renal and cardiac function. Informed consent was
obtained in accordance to local regulatory requirements, and with
the Declaration of Helsinki.
Treatment and dose escalation
SAM486A (Novartis Pharma AG) was supplied as vials
containing 10 or 50 mg of freeze-dried, light yellow powder for
reconstitution in a dextrose solution. The drug was diluted in 1000
ml 5% dextrose for 1 day of treatment. Treatment was given to
cohorts of patients (minimum size 2–3 patients) as a 120 h contin-
uous infusion every 4 weeks. A maximum of six cycles was fore-
seen. Dosing began at 3 mg m–2 cycle–1, calculated as one third of
the human equivalent of the no-adverse-effect level in the rat, i.e.
0.06 mg kg–1 day–1 (unpublished). Dose escalation was performed
in increments of 100–50% if none or minor grade 1 toxicity (NIH
common toxicity criteria, CTC) was observed, and by 33–22%
increments if grade 2 or higher toxicity occurred. In case of grade
2 or greater toxicity cohort size was expanded to six patients. Dose
escalation was continued until dose-limiting toxicity was
observed. Escalation decisions were made jointly between investi-
gators and sponsor following assessment of safety and pharmaco-
kinetic data at each cohort.
Dose-limiting toxicity and maximum tolerated dose
A nontolerated dose level was defined as a dose level on which,
among all treated patients (maximum six), either at least three had
grade 3 haematological toxicity, or at least two had grade 4 haema-
tological toxicity; or at least three had grade 3 non-haematological
toxicity; or at least one patient had grade 4 non-haematological
toxicity. The maximum tolerated dose (MTD), and hence, recom-
mended dose for Phase II trials, was defined as the highest dose
not associated with dose-limiting toxicity as described above.
SAM486A/5FU combination
Patients who received more than two courses were to have 5-
Fluorouracil (5FU) added to their treatment from the third cycle
onwards, based on preclinical data which showed additive antipro-
liferative action when these two drugs were given together. They
received five daily bolus injections of 5FU at a daily dose of 
500 mg m–2 day–1, administered in combination with SAM486A
starting at cycle three, and continuing as long as the patient
remained in the trial.
Evaluation of safety and efficacy
Safety was assessed by monitoring of vital signs and ECG daily
during infusion, and weekly thereafter. Haematological and
biochemical parameters were routinely monitored weekly. Physical
examination was performed weekly. LVEF was monitored every
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Figure 1 Polyamine biosynthetic pathwaysecond cycle or at discontinuation. Monitoring of adverse events
was continuous during the patient’s participation in the trial.
Efficacy was measured by assessment of overall tumour
response using UICC criteria. Additionally biological (tumour)
markers were measured when appropriate. Fluorodeoxy glucose
Positron emission tomography (FDG-PET) was performed in two
patients.
Pharmacokinetic sampling and analysis
SAM486A was measured in plasma and urine using a standardized
methodology previously described (Degen and Zbinden, 1996).
During the first cycle, all patients underwent pharmacokinetic
sampling; those who received a third cycle of treatment with the
addition of 5FU had repeated pharmacokinetics during that cycle.
Venous blood samples of 5 ml were collected in lithium or sodium
heparin coated tubes prior to start of the infusion (0 h), at day 4,
then 5, 15, 30 min, 1, 2, 4, 6, 8, 12 and 24 h after the end of the
infusion. During the first cycle (and third when 5FU was given),
urine was also collected in three 8-h samples on day 1, following
the administration of SAM486A. For each fraction, the total
volume was recorded and a 10 ml aliquot was stored at –20° C until
pharmacokinetic analysis.
The pharmacokinetic parameters Cmax, AUC((0-∞ ) and t1/2 were
determined by non-compartmental analysis using WinNonlin
Professional (Version 1.5) software (Scientific Consulting, Inc).
Descriptive statistics of the pharmacokinetic parameters were
calculated and included mean, SD, median and range (minimum
and maximum). The data was also analysed by linear regression.
Pharmacodynamic sampling and analysis
Blood samples were collected during the first treatment cycle for
measurement of polyamines and SAMDC activity. Blood samples
(10 ml) were taken at baseline, 72 h and 120 h after the start of
SAM486A infusion, and at days 7–8, 14, 21 and 28 after the start
of treatment. Polyamine pools and SAMDC activity were
measured in leukocytes using a published methodology (van den
Berg et al, 1987). Analysis was descriptive only.
FDG-PET scans
2-{18F} fluoro-2-deoxy D-glucose PET was to be performed at
University Hospital, Groningen, and University Hospital, Leuven,
on consenting patients receiving the recommended dose for Phase
II trials. Patients were scanned at baseline, not more than 72 h
before the start of the CGP 48664 infusion, and 2–3 days
following the first infusion.
{18F}-FDG was synthesized under strict radiopharmaceutical
controls using the method of Hamacher et al (1986). Statistical
analysis was performed using standardized uptake values
(Woodword et al, 1975) and Patlak analysis (Patlak et al, 1983).
RESULTS
Patient characteristics
From 7 December 1995 to 31 march 1998, 39 patients were
enrolled into the study from two centres. All were caucasian, 26
males and 13 females. Only four patients (10%) had not received
prior anticancer therapy. Patient characteristics are described in
Table 1.
Dose escalation and MTD of SAM486A monotherapy
Ten cohorts of 2–6 patients were studied at increasing dose levels
ranging from 3–700 mg m–2 cycle–1. Nine patients had only one
cycle of treatment, 21 (54%) had two, and three patients in each
case had 3, 4 and 6 cycles. Dose escalation started at 3 mg m–2
cycle–1 and increased in 100–75% steps to 700 mg m–2 cycle–1.
From this dose level two dose de-escalations to 550 mg m–2
cycle–1, then back to 400 mg m–2 cycle–1 were performed due to
appearance of dose-limiting granulocytopenia at the top two dose
levels. The MTD of SAM486A was defined as 400 mg m–2 cycle–1.
The number of patients and cumulative dose per dose level is
shown in Table 2.
Safety
Haematological toxicity
Granulocytopenia was the primary toxicity observed as a result of
SAM486A administration. None of the two patients treated at 
400 mg m–2 cycle–1 during the dose-escalation part of the study
experienced haematological toxicity. However, some evidence of
haematological toxicity was observed at this level among the four
patients subsequently entered in this cohort during the dose de-
escalation part of the study (one patient experienced transient
grade 3 granulocytopenia, another patient grade 1 granulocyto-
penia). Of the six patients enrolled to receive a dose of 550 mg m–2
cycle–1, four experienced grade 3 or 4 granulocytopenia, and three
of these were grade 4. At the highest dose level tested (700 mg m–2
cycle–1) three out of five patients experienced grade 4 granulocy-
topenia. The median day of granulocyte nadir was day 21 of the
cycle. Fever associated with granulocytopenia was noted in three
cases. Spontaneous recovery was observed, usually within 1 week
of nadir and without administration of growth factors, although
antibiotics were administered in two of these cases.
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Table 1 Patient characteristics
Sex
Male 26 pts
Female 13 pts
Median age (range) 55 years (22–78)
Performance status at baseline
0 15 pts
1 19 pts
2 5 pts
Primary diagnosis
Malignant melanoma 7 pts
Pulmonary carcinoma 4 pts
Renal carcinoma 4 pts
Breast carcinoma 4 pts
Colorectal carcinoma 4 pts
Sarcoma 3 pts
Adenocarcinoma of unknown primary site 3 pts
Other 10 pts
Prior anticancer therapy
none 4 pts
Surgery 24 pts
Chemotherapy 34 pts
Radiotherapy 22 pts
Immunotherapy 4 pts
Hormonal therapy 10 ptsThere is a clear relationship between dose and incidence of
haematological toxicity, as shown in Table 3. Thrombocytopenia
was observed in five patients. In three of these patients granulo-
cytopenia and leukopenia were also observed. Anaemia was noted
in 54% of patients. However, grade 3–4 anaemia was noted only in
four patients and represented worsening from grade 1 or 2 anaemia
present at baseline in all cases.
Non-haematological toxicity
The most common non-haematological adverse events which were
considered related to SAM486A administration were nausea
(26%), vomiting (21%), fatigue (26%) and anorexia (13%). Drug-
related nausea was present throughout the treatment cycle,
whereas fatigue, anorexia and vomiting were reported more
frequently after the infusion (Table 4). Drug-related nausea occur-
ring during the infusion was observed only in the three highest
dose groups, whereas post-infusion nausea was also observed at
lower dose levels. When anti-emetic therapy was used it was found
to be effective in controlling these symptoms. Nausea and
vomiting were of mild to moderate severity, as were the vast
majority of the adverse events observed. Grade 3 fatigue was
observed in only two patients (one at 400 mg m–2 cycle–1 and
another at 700 mg m–2 cycle–1), grade 3 anorexia was observed in
one patient at 550 mg m–2 cycle–1.
Grade 2–4 abnormalities in one or more liver function tests,
particularly in alkaline phosphatase, gamma GT and LDH,
were observed in 20/39 (51%) patients. This finding is
tempered by the observation that some abnormality (grade 1
abnormality or greater) in one or more liver function tests was
observed at baseline in 30/39 (77%) patients, and in 20/39
(51%), two or more parameters were already abnormal at base-
line. Of the patients with abnormalities in one or more liver
function tests at baseline, 15 entered the study with docu-
mented tumour involvement in the liver. Hence, the overall
interpretation of liver function test abnormalities is
confounded by the disease status of the patient population
enrolled onto the study. Overall, there is little evidence for
increased incidence of grade 2 or worse abnormalities in liver
function tests with increased doses of SAM486A. There were
no significant drug-related changes in electrolytes or in renal
function, nor in LVEF. Only one patient experienced an
episode of atrial fibrillation after cycle 2. This patient had a
prior history of atrial fibrillation and the event was not consid-
ered related to the study drug.
Clinical efficacy
No complete or partial responses were recorded in any of the 39
patients. Three patients completed the full six cycles of treatment.
Of these, two received the combination 5FU/SAM486A from
cycle 3 onwards. Five patients recorded a best response of stable
disease. Of these, three received the combination 5FU/SAM486A
from cycle 3 onwards (see below).
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Table 2 Dose escalation scheme and cumulative dose by dose level
Dose level 1 2 3 4 5 6 7 8 9 10
Dose intended 3 6 12 24 48 96 200 400 700 550
mg m–2 cycle–1
Number of patients 3 4 3 3 4 3 2 6 5 6
Number of patients 2 3 1
receiving 5FU
Number of cycles given 6 15 10 6 10 6 8 10 13 6
(including cycles with
combination
SAM486A/5FU)
Cumulative dose (mg)
Median 11.3 40.5 72 82 188.75 330 1535 1154 1210 2113.25
Sum 31 157.8 229.8 242.5 815.5 985.5 3070 7465 7230 13314.5
Table 3 Haematological toxicity by dose level (brackets indicate occurrence with combination SAM486A/5FU)
SAM486A intended dose level (mg m–2 cycle–1)
3 6 12 24 48 96 200 400 550 700 Total (%)
Total no. of patients studied 3 4 3 3 4 3 2 6 6 5 39 (100)
No of patients receiving – 23– 1 ––––– –
5FU
Grade 3–4
Leukocytes (WBC) – (1) ––– – – –3 3 7 (18)
Granulocytes (AGC) – (1) ––– – – 1 4 3 9 (23)
Thrombocytes – 1 ––– – – –1 – 2 (5)
Haemoglobin –– 11––– – 1 1 4 (10)
Grade 1–4
Leukocytes (WBC) – (1) (1) –– –1 2 5 4 14 (36)
Granulocytes (AGC) – (1) (1) –– ––2 4 4 12 (31)
Thrombocytes (platelets) – 1 (1) –– –––1 2 5 (10)
Haemoglobin 2 2 2 3 2 1 – 3 4 2 21 (54)Measurements of tumour markers were evaluable in only six
patients (CEA in four patients, CA 15.3 in two patients). No trends
towards decreases in post-baseline values were observed.
FDG-Positron Emission Tomography (PET) was performed in
only three patients at dose level 400 mg m–2 cycle–1, In two patients,
PET scan following the first 5-day infusion was performed (2 days
following end of infusion). Results were suggestive of stable
disease at best (not shown). Both patients discontinued due to
disease progression after 1–2 cycles of SAM486A treatment,
respectively. The results reflect the refractory nature of disease in
these patients and possibly suggest the need to further optimize the
time at which the post-treatment scan is performed.
Clinical experience with the combination of SAM486A
and 5FU
Per protocol, six patients received combined treatment with
SAM486A and 5FU from cycle 3 (two at a dose of SAM486A of 6
mg m–2 cycle–1, three at 12 mg m–2 cycle–1 and one at 48 mg m–2
cycle–1). Two of them experienced a severe toxicity. In one patient at
6 mg m–2 cycle–1 SAM486A, a grade 4 granulocytopenia was
observed on day 20 of the first combination cycle. Following 5FU
dose reduction to 300 mg m–2 day–1 for 5 consecutive days (vs the
original dose of 500 mg m–2 day–1) the patient received a further
three cycles of combination treatment without recurrence of myelo-
suppression. A second patient receiving 12 mg m–2 cycle–1 devel-
oped a grade 3 mucositis, which resolved by the end of the cycle 
and did not recur upon rechallenge with a reduced dose of 5FU 
(300 mg m–2 day–1) during cycle 4. Consequently, as an interaction
between both drugs could not be ruled out at this early stage, the study
of the combination was suspended (blood levels of SAM486A were
inconclusive, all below detection limits at these low-dose levels).
Pharmacokinetics and pharmacodynamics
The first 10 patients included at lowest dose levels had plasma
SAM486A concentrations below the limit of quantitation during
significant portions of the sampling interval. Mean plasma drug
concentration – time profiles for dose levels 24–700 mg m–2
cycle–1 are shown in Figure 2. Although there is substantial vari-
ability, both AUC and Cmax are linearly related to dose, as illus-
trated in Figure 3. In both cases the regression line passes close to
the origin (intercept is low). The dose per cycle explained 68% and
70% of the AUC and Cmax variabilities, respectively, as shown by
the R2 statistic. Mean terminal elimination half-life, in contrast,
did not appear to be related to dose. For all patients included in the
analysis the t1/2 was 48.6 h, with a standard deviation of 23.1 h.
Approximately 3% of the total drug administered was excreted in
the urine on day 1.
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Table 4 Non-haematological toxicity (considered related to SAM486A) by dose level (brackets indicate occurrence with combination SAM486A/5FU)
SAM486A intended dose level (mg m–2 cycle–1)
3 6 12 24 48 96 200 400 550 700 Total (%)
Total No. of patients studied 3 4 3 3 4 3 2 6 6 5 39 (100)
No. of patients receiving – 23 – 1 –––––
5FU
Grade 3–4
During infusion (day 1–5)
Condition aggravated –– ––– –––– 1 1 (3)
Asthenia –– ––– –––1 – 1 (3)
Vesicular rash –– ––– –––– 1 1 (3)
Vomiting –– ––– –––– 1 1 (3)
After infusion (day 6–28)
Fatigue –– ––– ––1 – 1 2 (5)
Condition aggravated –– ––– –––1 – 1 (3)
Mucositis nos –– (1) –– –––––1 (3)
Atrial fibrillation –– ––– –––1 – 1 (3)
Anorexia –– ––– –––1 – 1 (3)
Dementia –– ––– –––– 1 1 (3)
Somnolence –– ––– –––– 1 1 (3)
Dyspnea –– ––– –––– 1 1 (3)
Vesicular rash –– ––– –––– 1 1 (3)
Grade 1–4 (most common > 10%)
During infusion (days 1–5)
Nausea –– ––– ––1 2 2 5 (13)
After infusion (days 6–28)
Nausea – 1 – 1 (1) 1 – 1 3 2 10 (26)
Fatigue 1 1 1 1 –– – 2 2 2 10 (26)
Vomiting –– –1 – 1 ––3 3 8 (21)
Anorexia 1 –– – –– – 31– 5 (13)
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Plasma levels observed in this study far exceeded the IC50 of
0.0047 µ M (1.1 ng ml–1) required in in vitro experiments for inhi-
bition of SAMDC, suggesting that biologically relevant levels
were achievable at a dose of 200 mg m–2 cycle–1 but were more
sustained at doses of 400 mg m–2 cycle–1 and above.
Correlative analysis between pharmacokinetic parameters and
adverse events showed that doses of 550 and 700 mg m–2 cycle–1
and, most strikingly, AUC > 60 000 h ng ml–1 correlated with
grade 3 or 4 granulocytopenia (correlation coefficient 0.5814 and
0.6931, respectively, Figure 4. For Cmax, a trend is apparent toward
greater incidence of granulocytopenia at higher Cmax (correlation
coefficient 0.6794). In contrast, no correlations between pharma-
cokinetic parameters and the adverse events nausea and vomiting,
fatigue and anorexia were found.
With respect to pharmacodynamic assessments, the polymines
putrescine, spermidine and spermine and SAMDC activity were
measured in peripheral blood leukocytes. The data suggest a trend
towards increased levels of putrescine following the treatment
period at doses of 400 mg m–2 cycle–1 and above in 10 of the 11
patients evaluable (in contrast, such an increase was seen in six of
the 12 patients evaluable treated at doses of 3–200 mg m–2 cycle–1).
However, the interpatient variability was marked in terms of both
the magnitude of the increase and its time course, and furthermore
the expected concomitant decrease in the higher polyamines sper-
midine and spermine could not be detected.
SAMDC activity showed a marginal trend towards an increase in
some patients (nine of 18 patients and eight of 13 patients evaluable,
and treated at doses up to 200 mg m–2 cycle–1 and at doses of 
400 mg m–2 cycle–1 and above, respectively), followed by a decrease
in values during the 28-day treatment cycle. There was no clear-cut
dose–response relationship. Such an increase is consistent with drug
action and is thought to be due to an artefactual stabilization of the
SAMDC enzyme. However, again, interpatient variability makes
further interpretation of these observations difficult.
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Figure 4 Correlations between granulocytopenia and dose (A) and granulocytopenia and AUC (B)DISCUSSION
The primary objectives of this phase I trial, namely to evaluate
safety and tolerability of SAM486A given as a 5-day continuous
infusion in a population of patients with advanced cancer, and to
determine the MTD, have been fulfilled. SAM486A is well toler-
ated up to and including a dose of 400 mg m–2 cycle–1, and cycles
can be repeated every 4 weeks without evidence of cumulative
toxicity or necessity for cycle interruption. Dose-limiting toxicity
is observed at doses of 550 mg m–2 cycle–1 and 700 mg m–2 cycle–1
and consists of reversible, uncomplicated granulocytopenia. This
is clearly dose-dependent, being observed almost exclusively
within the top three dose levels and becoming intolerable in the 
top two dose levels explored. The granulocytopenia is relatively
late in onset with a median nadir occurring on cycle day 21 
(given the caveat of weekly sampling only in most patients).
Granulocytopenia was uncomplicated by fever in most cases and
recovery was usually observed within 7 days. The MTD of 
400 mg m–2 cycle–1 induced grade 3 granulocytopenia in one of six
patients: this was manageable and furthermore not dose-limiting
as defined by protocol. However it must be recognized that mild
granulocytopenia may well be expected in some patients when
SAM486A is given at this dose and schedule.
Mild to moderate nausea and vomiting was also reported
throughout the cycle, occurring in 15% during infusion, and in
31% thereafter. The causal relationship with therapy was not
always evident and could, at least in some cases, merely be
ascribed to the disease. Anti-emetic therapy was given on a
number of occasions and was effective in the control of potential
further emetic episodes. However, given the mild nature of most
cases, prophylactic anti-emetic therapy is not likely to be indicated
based upon these observations. Preclinical animal testing did not
indicate that SAM486A may induce emesis.
Fatigue was also observed as a frequent event, occurring in 51%
of all patients after the infusion. This effect was considered by the
clinicians as possibly due to study drug in about half (26%) of
these patients. The general intolerability of doses 550 and 700 mg
m–2 cycle–1 is also reflected by the observation that eight of the 11
patients treated at these dose levels experienced some worsening
in performance status.
On the basis of encouraging preclinical data, patients proceeding
to a third cycle of SAM486A treatment were offered daily bolus
5FU (at a dose of 500 mg m–2 day–1 for 5 consecutive days) in
combination with the continuous infusion SAM486A. However, this
combination was explored only at low-dose levels of SAM486A, as
grade 4 granulocytopenia and grade 3 mucositis were observed at
the second and third SAM486A dose levels, respectively, leading to
the suspension of this combination in this protocol. These toxicities,
particularly mucositis, are known side-effects of 5 FU treatment but
have also been observed in patients treated with MGBG, of which
SAM486A is an analog. Although no mucositis was reported with
single-agent SAM486A at any dose, and no granulocytopenia with
single-agent SAM486A at doses where the combination was given,
an additive effect cannot be ruled out. The question of potential
interaction between SAM486A and 5 FU needs to be addressed in a
study designed specifically to address this issue, and further devel-
opment in indications where 5FU is commonly used (e.g. colorectal
cancer) is warranted.
SAM486A undergoes multiphasic elimination from the plasma,
characterized by an initial rapid decline followed by a gradual
prolonged decline. The mean terminal elimination half-life of
SAM486A on this schedule is approximately 2 days and Cmax and
AUC are linearly related to dose. Furthermore, the plasma levels
achieved at doses ≥ 200 mg m–2 cycle–1 exceeded by far the IC50
for in vitro inhibition of SAMDC (0.0047 µ M). This finding
suggests that biologically relevant levels of SAM486 are achiev-
able in man, but this will need to be confirmed by direct measure-
ment of drug level in tumour biopsies from treated patients. Of
interest, in the study by Siu et al (1998) investigating a daily
regimen over 5 consecutive days, a potent inhibition of SAMDC
(reflected by a marked decrease in decarboxylated S-adenosyl
methionine) was shown in one patient with metastatic melanoma
who had pre- and post-treatment tumour biopsies (Porter et al,
1998) The disposition of SAM486A in rats and dogs was charac-
terized by rapid clearance from blood and plasma, an extensive
distribution throughout the body, accumulation in various tissues,
particularly in the liver, incomplete (predominantly renal) excre-
tion and a low degree of metabolism. Elimination from tissues was
markedly slower than from blood and plasma. This relatively long
terminal elimination half-life is consistent with the preclinical
findings. The linearity of the pharmacokinetic parameters Cmax and
AUC with dose implies that there are no saturable, inhibited or
induced processes involved with the distribution and elimination
of SAM486A. This would facilitate the adjustment of doses to
achieve targeted plasma drug levels or exposure (AUC).
The dose-limiting toxicity, granulocytopenia, is associated with
doses greater than 400 mg ml–2 cycle–1 and AUC > 60 000 h ng
m–1. This clear relationship suggests that PK monitoring might be
helpful in adjusting the dose in response to incidences of granulo-
cytopenia. Correlative analysis suggests that there is no correlation
of PK parameters with incidence and severity of nausea and
vomiting, fatigue and anorexia. This suggests that these adverse
events may not be related to exposure to SAM486A (i.e. no
dose–event relationship).
No evidence of antitumour activity in the form of objective
tumour regression was observed in this heterogeneous and heavily
pretreated population of patients with advanced cancer. However,
stable disease was recorded as best response in five patients.
Repeated positron emission topography (PET) scanning using
fluoro-deoxy glucose was performed on only two patients treated
at the highest dose levels following the first 5-day infusion. The
observed results were suggestive of disease stabilization at best.
Despite these inconclusive results, the technique per se remains a
powerful technology for the detection of subclinical drug activity
by investigating tumour metabolism. Thus, with some refinement,
it would seem worthwhile continuing to explore this technique as
part of future clinical studies, in a more favourable population of
patients likely to respond to treatment, perhaps with modification
of the scanning protocol to investigate later time-points following
end of infusion.
Investigation of polyamine pools in peripheral blood leukocytes
was hampered by a high interpatient variability at any dose of
SAM486A. Changes were inconsistent and not uniformly dose-
related, with some possible trends consistent with the proposed
mechanism of action in selected polyamine parameters. As shown
in experimental models, the dependence of cell survival on endoge-
nously synthesized polyamines in a given tissue appears to be a
function of its proliferative rate (Hassels et al, 1989). Thus, in view
of the inconsistency between perceived trends, and because circu-
lating leucocytes may be irrelevant as surrogate pharmacodynamic
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marker of tumour response, it does not appear that polyamine
levels in peripheral blood leukocytes is a suitable means to
monitor pharmacodynamic action of SAM486A.
In conclusion, the recommended dose for further phase II–III
studies using this schedule is 400 mg m–2 cycle–1, to be repeated
every 4 weeks. Mild reversible haematotoxicity (leucopenia and
thrombopenia), fatigue, nausea and vomiting may be observed, the
latter responding well to standard anti-emetic treatments. At
higher dosages, severe (grade 3 or 4) neutropenia becomes the
dose-limiting toxicity. Given the good tolerability profile of
SAM486A and the promising antitumour activity observed in
preclinical models, single-agent testing in a phase II setting is
clearly warranted. The optimal dosing and scheduling of a
SAM486A/5-FU combination requires further phase I investiga-
tion, but the observation of disease stabilization in patients
receiving this combination points to the need for evaluation of this
combination in indications where 5FU is commonly used, such as
advanced colorectal cancer.
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